<a href="https://www.fiercebiotech.com/biotech/facing-looming-xtandi-patent-cliff-astellas-pins-hopes-more-deals-while-still-cutting-costs" hreflang="en">Facing looming Xtandi patent cliff, Astellas pins hopes on more deals while still cutting costs</a>
Astellas Pharma is preparing for a decline in sales from its prostate cancer drug Xtandi due to an impending patent expiration by pursuing new licensing deals and potential acquisitions while implementing cost-cutting measures. The company aims to achieve record-high revenue by the mid-2030s through a strategic plan focused on enhancing its pipeline and expanding its portfolio of strategic brands.
Astellas Pharma is strategically preparing for the revenue decline expected from the Xtandi patent cliff by pursuing licensing deals and potential acquisitions of "synergistic" and "moderately derisked" assets, particularly in pre-defined therapeutic areas. This approach, alongside their focus on cost reduction and driving growth from their strategic brands, signals significant investment opportunities in companies with assets that align with Astellas' therapeutic priorities and capabilities. For a professional interested in healthtech and biotech, this presents a potential opportunity to explore partnerships or investments in companies that fit Astellas' acquisition criteria.